<DOC>
	<DOCNO>NCT00745225</DOCNO>
	<brief_summary>To study whether peroxisome proliferator-activated receptor-gamma activation peritoneal dialysis patient reduce inflammation , atherosclerosis , calcification improve survival peritoneal dialysis patient</brief_summary>
	<brief_title>Peroxisome Proliferator-Activated Receptor-Gamma Activation Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Peritoneal dialysis patient increase risk cardiovascular morbidity mortality relate presence accelerate atherosclerosis . Other traditional cardiovascular risk factor , increase evidence inflammation associate development atherosclerosis cardiovascular event general dialysis population . C-reactive protein predictive high all-cause mortality cardiovascular mortality , independent cardiovascular risk factor atherosclerotic vascular disease . As considerable proportion peritoneal dialysis patient show elevated C-reactive protein , raise important question whether lower C-reactive protein cardiovascular survival benefit patient . On hand , insulin resistance associate hyperinsulinemia frequently observe chronic renal failure dialysis patient . Although exact mechanism insulin resistance need evaluation , study indicate insulin resistance important cardiovascular risk factor outcome predictor general dialysis population . Moreover , recent evidence indicate association chronic inflammation insulin resistance although exact interrelationship remain unclear . The peroxisome proliferator-activated receptor-gamma ( PPAR-g ) member nuclear receptor family ligand-dependent transcription factor . PPAR-g highly express adipose tissue clinical study confirm efficacy specific ligands PPAR-gamma , namely thiazolidinediones ( TZD ) , improve insulin sensitivity . Recent experimental clinical study demonstrate TZD anti-inflammatory anti-atherosclerotic property insulin sensitize effect type 2 diabetic . We hypothesize modulation PPAR-g activity may novel therapeutic strategy reduce inflammation improve insulin sensitivity may retard progression atherosclerosis possibly reduce mortality peritoneal dialysis patient .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Both prevalent patient patient newly start continuous peritoneal dialysis , without diabetes mellitus consider eligible study entry . For patient newly start chronic peritoneal dialysis , suitable recruitment study one month peritoneal dialysis . Patients provide inform consent study Patients underlie active malignancy Patients chronic liver disease liver cirrhosis Patients active infection Patients chronic active inflammatory disease systemic lupus erythematosus , rheumatoid arthritis Patients refuse study participation Patients underlie congenital heart disease rheumatic heart disease Patients poor general condition Patients plan live relate kidney transplant within 2 year Female patient pregnancy Patients history recurrent hypoglycemia Patients Class III IV congestive heart failure Patients already receive glitazones treatment screen visit</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>peritoneal dialysis , cardiovascular , PPAR-gamma</keyword>
</DOC>